United States: Two Herceptin® Patents Survive IPR: A Lesson In Separately Arguing Motivation To Combine And Reasonable Expectation Of Success

Last Updated: October 8 2018
Article by Lisa M. Mandrusiak

Motivation to combine and reasonable expectation of success are separate requirements that must be independently considered.  By capitalizing on shortcomings in the petitions related to separately arguing these issues, Genentech was able to save two of three patents covering its blockbuster drug Herceptin®.

Herceptin®, the brand name for the monoclonal antibody drug trastuzumab, has been federally approved since 1998 primarily for treating breast cancer. Herceptin® has been extremely successful for Genentech, earning approximately $2.5 billion in the U.S. and $6.5 billion globally in 2016.

Conventionally, trastuzumab treatments are given weekly. Genentech obtained two patents—U.S. Patent Nos. 6,627,196 and 7,371,379—that extend the dosing regimen to every three weeks. The ’196 patent was challenged in IPR2017-00804 by Hospira and Samsung Bioepsis (via joinder with IPR2017-01958), and in IPR2017-01139 by Celltrion. The ’379 patent was challenged in IPR2017-00805 by Hospira and Samsung Bioepsis (via joinder with IPR2017-01959), and in IPR2017-01140 by Celltrion. The issues for the ’196 and ’379 patents overlap substantially and will be discussed together, grouped by challenger.

Hospira and Samsung Bioepsis Petitions

Hospira and Samsung Bioepsis challenged the patents based on the old Herceptin® label in combination with two secondary references and the knowledge of one skilled in the art. Petitioners argued trastuzumab was widely known as an efficacious breast cancer treatment, as established by the three references. Petitioners then argued that, although the references only teach a weekly regimen, a skilled artisan “would nonetheless have been motivated to decrease the frequency of trastuzumab administration to once every three weeks for several reasons.” This argument was based on general knowledge that a more convenient (i.e., less frequent) dosing regimen would improve patient compliance and quality of life for terminally ill patients. And, a tri-weekly regimen would align with chemotherapy dosing schedules, reducing the number of trips necessary to the clinic. Petitioners also argued that arriving at the tri-weekly dosing schedule was merely a matter of routine calculation and optimization, supported by sample pharmacokinetic calculations.

The Board summarized the two main issues in the proceedings as (a) whether there would have been a motivation to extend the weekly dosing interval taught in the prior art to a tri-weekly dosing interval based on concerns about patient convenience and quality of life; and (b) whether there would have been a reasonable expectation of success in implementing this regimen based on petitioners’ expert’s pharmacokinetic analysis. The Board emphasized that these are distinct legal requirements and addressed these issues separately, citing Intelligent Bio-Systems, Inc. v. Illumina Cambridge, Ltd., 821 F.3d 1359, 1367 (Fed. Cir. 2016) (“One must have a motivation to combine accompanied by a reasonable expectation of achieving what is claimed in the patent-at-issue” and “the Board conflated two different legal concepts—reasonable expectation of success and motivation to combine”).

The Board was persuaded with regard to motivation to combine, noting that a skilled artisan “would have been motivated to extend the dosing interval for the simple (yet compelling) reasons that doing so would have been more cost-effective and less burdensome for the patient.”

But, the Board found that Hospira and Samsung Bioepsis did not establish a reasonable expectation of success based on their proposed pharmacokinetic analysis allegedly showing that efficacy of trastuzumab could be maintained with a three week dosing schedule. Genentech persuasively argued against these calculations, emphasizing that the calculations assume linear kinetics, but trastuzumab may have non-linear kinetics, and thus the relevant pharmacokinetic parameters do not remain constant. Genentech also reiterated there was nothing in the prior art to allow one skilled in the art to accurately predict whether the three-week dosing would be effective.

The Board agreed, noting the relative novelty of using antibodies as cancer treatments as of the priority date and the lack of any prior art references discussing the feasibility or viability of a tri-weekly antibody dosing regimen. Moreover, while petitioners’ calculations were based on “textbook” equations that were known in the actual pharmacokinetic analysis was not based in the prior art and considered to be “largely based on impermissible hindsight.” Furthermore, the prior art established that trastuzumab exhibits dose-dependent kinetics, and the very textbook relied upon notes that “dose-dependent and time-dependent kinetic behaviors defy easy quantitative description and prediction.” Petitioners submitted substantial evidence in their Reply attempting to support their theory, but the Board was unpersuaded, particularly based on contradictory statements in the evidence regarding uncertainty and attempts to generalize small molecule kinetics with antibody kinetics. Accordingly, the Board concluded that Petitioners did not establish the reasonable expectation of success required for obviousness.

Lessons for Practitioners

This case illustrates the importance of arguing and attacking motivation to combine and reasonable expectation of success separately. For petitioners, reasonable expectation of success must be clearly articulated with no hindsight bias, and care should be taken when extrapolating models to cover alternative scenarios. Genentech’s patent owner response provides a good example of how to persuasively attack reasonable expectation of success arguments, particularly with regard to drugs.

Celltrion Petitions

The Celltrion petitions provide an example of where these issues were not sufficiently argued separately. Here, the Board found that Celltrion did not sufficiently establish a motivation to combine the references, particularly with regard to modifying the claimed loading and maintenance doses. And because the Board found that Celltrion had not met its burden to show that an ordinary artisan would have been motivated to modify the dosage amount in the first instance, its reasonable expectation arguments, premised upon efficacy associated with the modified dosage, also failed. Moreover, Celltrion attempted to establish reasonable expectation of success for claims 24, 25, 29 and 30 in a single paragraph referring back to its analysis of claim 1. But those claims recited a different dosage and thus the arguments—which failed anyway—were insufficient.

Successful Petitions

Hospira (IPR2017-00737), Samsung Bioepsis (IPR2017-01969 by joinder with Hospira), and Celltrion (IPR2017-01122) were successful in challenging Genentech’s U.S. Patent No. 7,892,549, a third patent covering Herceptin®.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions